title: Nasopharyngeal carcinoma -- analysis of risk factors and immunological markers.
abstract: OBJECTIVE
  To analyze the risk factors associated with Nasopharyngeal Carcinoma (NPC)in patients admitted to the ENT Department at Coltea Clinical Hospital in order to assess the similarities and differences as compared to the epidemiological data internationally reported.
  
  
  METHODS
  This is a retrospective study on 178 cases that met the inclusion criteria from 2003 to 2011.
  
  
  CONCLUSIONS
  There are a number of specific characteristics noticed in our study group: a larger number of cases aged over 60 than younger patients; a linear fall in number of the cases aged between 30-39 years; approximately one third of the cases did not have any of the traditional risk factors; more than 10% of the cases were associated with lymphoma, etc.
  
  
  CONCLUSIONS
  The immunologic pattern of our patients presenting undifferentiated NPC is the following: MNF116, CK19, S100, CD34betaE12, Ki67, EBV positive. The rest of the markers were negative (CerB2, EGFR, COX2, p53, CK7, CD117, VGFR, PCNA, L26/CD20, UHCL1, CD15, CD30, VIM, TTF1, CLA, CK17, CEA, LMP, CD79a, EMA).
authors.affiliation: ENT Department, Coltea Clinical Hospital, Bucharest, Romania. ionangheldoc@yahoo.com
authors.forename: I
authors.initials: I
authors.lastname: Anghel
authors.forename: A G
authors.initials: AG
authors.lastname: Anghel
authors.forename: M
authors.initials: M
authors.lastname: Dumitru
authors.forename: C C
authors.initials: CC
authors.lastname: Soreanu
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000437:Alcoholism / Q000150:complications; D000914:Antibodies, Viral / Q000097:blood; D018952:Antigens, CD34 / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D002277:Carcinoma / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology* / Q000532:radiotherapy; D055088:Early Detection of Cancer; D020031:Epstein-Barr Virus Infections / Q000150:complications; D005260:Female; D015386:Hazardous Substances / Q000009:adverse effects; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D053539:Keratin-19 / Q000032:analysis; D007633:Keratins / Q000032:analysis; D019394:Ki-67 Antigen / Q000032:analysis; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000175:diagnosis* / Q000276:immunology* / Q000532:radiotherapy; D011237:Predictive Value of Tests; D015995:Prevalence; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012383:Romania / Q000453:epidemiology; D009418:S100 Proteins / Q000032:analysis; D012680:Sensitivity and Specificity; D017678:Sex Distribution; D012907:Smoking / Q000009:adverse effects
chemical_list: D000914:Antibodies, Viral; D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D015386:Hazardous Substances; D053539:Keratin-19; D019394:Ki-67 Antigen; D009418:S100 Proteins; C526516:cytokeratin MNF116, human; D007633:Keratins